Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Retained Earnings (2016 - 2025)

IGC Pharma (IGC) has disclosed Retained Earnings for 15 consecutive years, with -$4.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 41.06% to -$4.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.9 million, a 41.06% decrease, with the full-year FY2025 number at -$3.5 million, down 2.13% from a year prior.
  • Retained Earnings was -$4.9 million for Q3 2025 at IGC Pharma, down from -$3.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$2.8 million in Q1 2021 to a low of -$110.8 million in Q4 2023.
  • A 5-year average of -$31.0 million and a median of -$3.5 million in 2024 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 3291.68% in 2023, then surged 96.88% in 2024.
  • IGC Pharma's Retained Earnings stood at -$82.7 million in 2021, then skyrocketed by 95.85% to -$3.4 million in 2022, then crashed by 3129.74% to -$110.8 million in 2023, then soared by 96.88% to -$3.5 million in 2024, then tumbled by 40.33% to -$4.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Retained Earnings are -$4.9 million (Q3 2025), -$3.5 million (Q2 2025), and -$3.5 million (Q1 2025).